We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
-7.49%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.45B
AUM Growth
-$331M
(-12%)
Cap. Flow
-$447M
Cap. Flow
% of AUM
-18.22%
Top 10 Holdings %
Top 10 Hldgs %
43.96%
Holding
111
New
16
Increased
20
Reduced
24
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mirum Pharmaceuticals
MIRM
|
+$42.3M |
| 2 |
Rhythm Pharmaceuticals
RYTM
|
+$42.2M |
| 3 |
AERI
Aerie Pharmaceuticals
AERI
|
+$35.2M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$24.8M |
| 5 |
Centene
CNC
|
+$20.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Natera
NTRA
|
+$27.7M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
+$26M |
| 3 |
STAAR Surgical
STAA
|
+$25.8M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
+$25M |
| 5 |
NVTA
Invitae Corporation
NVTA
|
+$23.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 71.17% |
| 2 | Financials | 0.3% |
| 3 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $176M | 7.17% |
6,462,634
| – | – |
|
2
Viatris
VTRS
$20.1B
| $151M | 6.17% |
7,654,065
+189,738
| +3% | +$3.72M |
|
|
ORTX
3
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $106M | 4.32% |
892,360
| – | – |
|
4
Q32 Bio
QTTB
$255M
| $104M | 4.25% |
320,020
| – | – |
|
|
AERI
5
DELISTED
Aerie Pharmaceuticals
AERI
| $87.8M | 3.58% |
4,568,824
+1,535,837
| +51% | +$35.2M |
|
|
6
Rhythm Pharmaceuticals
RYTM
$7.31B
| $55.9M | 2.28% |
2,589,291
+1,965,358
| +315% | +$42.2M |
|
7
Brookdale Senior Living
BKD
$3.58B
| $54.6M | 2.23% |
7,207,239
| – | – |
|
|
XENT
8
DELISTED
Intersect ENT, Inc
XENT
| $52.9M | 2.16% |
3,109,004
| – | – |
|
|
XLRN
9
DELISTED
Acceleron Pharma
XLRN
| $51.6M | 2.1% |
1,305,174
| – | – |
|
|
MYOK
10
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $51.2M | 2.09% |
981,430
-15,570
| -2% | -$828K |
|
|
IMMU
11
DELISTED
Immunomedics Inc
IMMU
| $42.6M | 1.74% |
3,214,000
-1,771,383
| -36% | -$26M |
|
|
RARX
12
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $40.9M | 1.67% |
1,728,019
+15,019
| +0.9% | +$445K |
|
|
13
Mirum Pharmaceuticals
MIRM
$7.25B
| $34.7M | 1.41% |
+3,448,912
| New | +$42.3M |
|
14
argenx
ARGX
$53.8B
| $32M | 1.31% |
281,000
| – | – |
|
|
SILK
15
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $31.9M | 1.3% |
979,480
+480,450
| +96% | +$19.1M |
|
16
Vericel Corp
VCEL
$2.38B
| $31.5M | 1.28% |
2,081,000
+11,399
| +0.6% | +$199K |
|
17
Coherus Oncology
CHRS
$216M
| $31.2M | 1.27% |
1,540,305
-137,717
| -8% | -$2.75M |
|
|
18
Centene
CNC
$32.8B
| $31.2M | 1.27% |
720,400
+417,400
| +138% | +$20.3M |
|
19
Fate Therapeutics
FATE
$324M
| $30.3M | 1.24% |
1,952,897
+250,000
| +15% | +$4.79M |
|
20
Alector
ALEC
$167M
| $29.9M | 1.22% |
2,076,812
+329,889
| +19% | +$5.96M |
|
21
Sarepta Therapeutics
SRPT
$1.82B
| $28.8M | 1.17% |
382,000
+72,975
| +24% | +$8.62M |
|
|
SEM
22
DELISTED
Select Medical
SEM
| $28.4M | 1.16% |
3,181,368
-611,418
| -16% | -$5.34M |
|
|
BPMC
23
DELISTED
Blueprint Medicines
BPMC
| $27.7M | 1.13% |
377,200
-14,054
| -4% | -$1.21M |
|
|
DBVT
24
DBV Technologies
DBVT
$870M
| $27.5M | 1.12% |
320,122
| – | – |
|
|
SIEN
25
DELISTED
Sientra, Inc.
SIEN
| $26.8M | 1.09% |
413,747
-51,484
| -11% | -$3.27M |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q3 2019 Portfolio in Review
As of Q3 2019, Deerfield Management held 111 positions worth $2.45B, down 12% from $2.78B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Deerfield Management withdrew a net $447M in Q3 2019, closing 16 positions and reducing 24 holdings. Its most notable exit was Natera, an estimated $27.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 68% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Deerfield Management opened a new position in Mirum Pharmaceuticals worth $34.7M.
- Deerfield Management's largest Q3 2019 buy was Mirum Pharmaceuticals: 3,448,912 shares worth $34.7M.
- Deerfield Management added most to Rhythm Pharmaceuticals in Q3 2019, an estimated $42.2M increase.
- Deerfield Management's biggest Q3 2019 reduction was Immunomedics Inc, cutting an estimated $26M.
- Deerfield Management fully exited Natera in Q3 2019, selling an estimated $27.7M.
- Deerfield Management's ten largest holdings make up 44% of its $2.45B portfolio in Q3 2019.
- Deerfield Management opened 16 new positions and closed 16 in Q3 2019.
- Deerfield Management's portfolio value fell 12% quarter-over-quarter to $2.45B.
Based on Deerfield Management's 13F filing for Q3 2019, filed 14 Nov 2019.